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Abstract: Lower extremity complications in persons with diabetes have become an increas-
ingly signiﬁcant public health concern in both the developed and developing world. These 
complications, beginning with neuropathy and subsequent diabetic foot wounds frequently 
lead to infection and lower extremity amputation even in the absence of critical limb ischemia. 
In order to diminish the detrimental consequences associated with diabetic foot ulcers, a com-
mon-sense-based treatment approach must be implemented. Many of the etiological factors 
contributing to the formation of diabetic foot ulceration may be identiﬁed using simple, inex-
pensive equipment in a clinical setting. Prevention of diabetic foot ulcers can be accomplished 
in a primary care setting with a brief history and screening for loss of protective sensation via 
the Semmes-Weinstein monoﬁlament. Specialist clinics may quantify neuropathy, plantar foot 
pressure, and assess vascular status with Doppler ultrasound and ankle-brachial blood pressure 
indices. These measurements, in conjunction with other ﬁndings from the history and physi-
cal examination, may enable clinicians to stratify patients based on risk and help determine 
the type of intervention. Other effective clinical interventions may include patient education, 
optimizing glycemic control, smoking cessation, and diligent foot care. Recent technological 
advanced combined with better understanding of the wound healing process have resulted in 
a myriad of advanced wound healing modalities in the treatment of diabetic foot ulcers. How-
ever, it is imperative to remember the fundamental basics in the healing of diabetic foot ulcers: 
adequate perfusion, debridement, infection control, and pressure mitigation. Early recognition 
of the etiological factors along with prompt management of diabetic foot ulcers is essential for 
successful outcome.
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Introduction
The rapid rise in the incidence of diabetes, a serious life-long condition, is of alarming 
concern to health care professionals. Recent data from the Center of Disease Control 
and Prevention approximate that 20.8 million people, roughly 7% of the United States 
population, have diabetes (2005). In 2005 alone, 1.5 million new cases of diabetes were 
diagnosed in people aged 20 years or older (2005). Diabetes mellitus is a disease known 
for its multifaceted complications, and foot ulceration, which often results in lower 
extremity amputations, is one of the most common complications associated with the 
disease (Boulton and Vileikyte 2000; Reiber 2001; Dang and Boulton 2003; Pinzur et al 
2005). The prevalence of foot ulcers ranges from 4% to 10% among persons diagnosed 
with diabetes mellitus (Singh et al 2005). This translates to an annual population-based 
incidence of 1.0% to 4.1%, and the lifetime incidence may be as high as 25% (Singh 
et al 2005). Diabetic foot ulcers frequently become infected and are a major cause of 
hospital admissions (Dang and Boulton 2003; Pinzur et al 2005). They also account Vascular Health and Risk Management 2007:3(1) 66
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for more than half of non-traumatic lower limb amputations 
in this patient population (Dang and Boulton 2003). Dia-
betic foot ulcers impose tremendous medical and ﬁnancial 
burden on our healthcare system with costs conservatively 
estimated as high as $45000 per patient (Stockl et al 2004). 
These estimations, however, do not include the deleterious 
psychosocial effects on the patient’s quality of life because 
of impaired mobility and substantial loss of productivity 
(Ragnarson Tennvall and Apelqvist 2004). Ulcerations are 
pivotal events in limb loss for two important reasons. They 
allow an avenue for infection (Armstrong and Lipsky 2004), 
and can cause progressive tissue necrosis and poor wound 
healing in the presence of critical ischemia. Approximately 
56% of diabetic foot ulcerations become infected (Block 
1981; Gibbons and Eliopoulos 1984; Smith et al 1987) and 
20% of these patients with infected foot wounds end up 
with some type of lower extremity amputation. Therefore 
the timely prevention and healing of diabetic ulcerations are 
fundamental for amputation prevention (Schwegler et al 2002; 
Wu et al 2005). This manuscript will focus on the prevention 
and treatment of diabetic foot ulcerations.
Prevention
Prevention and prophylactic foot care have been advocated 
to decrease patient morbidity, the utilization of expensive 
resources, as well as the risk for amputations (Pinzur et al 
2005). These interventions, which include the identiﬁcation 
of risk factors, patient education, and intensive podiatric care 
(Moreland et al 2004; Singh et al 2005), have been shown to 
be cost effective or even cost saving (Ragnarson Tennvall and 
Apelqvist 2004). Increased awareness of the potential inﬂu-
ence of reimbursement systems on prevention, management, 
and outcomes of diabetic foot lesions has improved in recent 
years (Ragnarson Tennvall and Apelqvist 2004).
Diabetes is a multifactoral disease and the multi- 
disciplinary approach has been advocated for the comprehen-
sive treatment of diabetes and prevention of its complications 
(Ronnemaa et al 1997; Plank et al 2003). Patients with dia-
betes who present for care should be under the concomitant 
management of a primary care physician with appropriate re-
ferrals to an endocrinologist, ophthalmologist, nephrologists, 
vascular surgeon, podiatrist, physical therapist, nutritionist, 
and a diabetic educator to help ensure adequate care (Dang 
and Boulton 2003; Schaper et al 2003; Singh et al 2005; Van 
Damme and Limet 2005). These different perspectives and 
approaches were the basis for the American Diabetes Asso-
ciation Position Statements and the International Consensus 
on the Diabetic Foot, resulting in a worldwide network of 
professionals involved in the management of diabetic patients 
with foot problems (Schaper et al 2003). Applying evidence-
based multidisciplinary treatment has been shown to result 
in a 50% reduction of major lower-limb amputation in this 
high risk group (Van Damme and Limet 2005).
Lavery et al implemented a lower extremity disease 
management program consisting of screening and treatment 
protocols for the diabetic foot in a managed care organization 
and noted its effectiveness to reduce hospitalizations and 
amputations (Lavery et al 2005). Based on the presence or 
absence of diabetic neuropathy, peripheral vascular disease, 
foot deformities and pressures, as well as the history of lower 
extremity pathology, the authors stratiﬁed patients into low 
and high-risk groups, and implemented preventive or acute 
care protocols (Lavery et al 2005). They noted a 47.4% de-
crease in the incidence of amputations from 12.89 per 1000 
diabetics per year to 6.18 (p < 0.05), and a 37.8% decrease 
in foot related hospital admissions, from 22.86 per 1000 
members per year to 14.23 (37.8%), after implementation of 
the disease management program (Lavery et al 2005). They 
further noted a 21.7% reduction in the average patient length 
of stay from 4.75 to 3.72 days (p < 0.05), a 69.8% reduction 
in the number of skilled nursing facility admissions per 1000 
members per year, and a 38.2% reduction in the average 
length of stay in a skilled nursing facility 8.72 to 6.52 days 
(p < 0.05) (Lavery et al 2005).
Singh et al conducted a literature review of the efﬁcacy of 
various diabetic foot ulcer prevention methods in the primary 
care setting from articles published between January 1980 and 
April 2004 available through EBSCO, MEDLINE, the Na-
tional Guideline Clearinghouse databases, Cochrane Library, 
and relevant Web sites (Singh et al 2005). The authors noted 
substantial evidence to support screening of all patients with 
diabetes to identify those at risk for foot ulceration (Singh et al 
2005). The authors further noted that patients may beneﬁt from 
certain prophylactic interventions, including patient education, 
prescription footwear, intensive podiatric care, and evaluation for 
surgical interventions (Singh et al 2005). However, the patient 
and their health care professional must be fully informed of their 
problems, understand the management process, and be willing to 
make the necessary lifestyle changes to minimize complications 
(Helfand 2003). 
A thorough history and physical is fundamental to iden-
tify risk factors for the development of diabetic foot ulcers. 
This includes an assessment of loss of protective sensation, 
foot structure, limited joint mobility, vascular status, and a 
history of previous foot ulceration, amputation or Charcot 
neuroarthropathy (Lavery et al 1998; Mayﬁeld et al 2003).Vascular Health and Risk Management 2007:3(1) 67
Foot ulcers in the diabetic patient
History
Known factors for foot ulcerations include a current ulcer, 
past history of previous ulceration, prior lower extrem-
ity amputation, or the presence of neuropathic fractures 
(Lavery et al 1998; Boyko et al 1999; Abbott et al 2002), 
which increase the risk for further ulceration, infection 
and subsequent amputation (Goldner 1960; Pecoraro   
zet al 1990; Lavery et al 1998). Within one year of wound 
healing following ulceration, up to 60% of patients with a 
positive ulceration history will develop another because 
the skin plantar to that site may be less resilient and less 
well fortiﬁed to accept repetitive stress and therefore more 
prone to subsequent breakdown (Helm et al 1991; Uccioli 
et al 1995). This population segment has the highest risk of 
developing subsequent foot ulceration (Lavery et al 1998; 
Peters and Lavery 2001) and is the easiest risk group to 
identify. This patient population is also the group most 
in need of frequent foot assessment, intensive education, 
therapeutic shoes, padded stockings and rigorous blood 
glucose control.
Foot exam
Annual foot examinations are recommended for all indi-
viduals with diabetes to identify high-risk foot conditions 
including peripheral vascular insufﬁciency, structural foot 
deformities, and loss of protective sensation for which 
speciﬁc interventions have been shown to be effective in 
reducing amputation risk (Mayﬁeld et al 2000).
Vascular exam
Peripheral arterial disease (PAD) is twice as common in per-
sons with diabetes as in persons without (Gregg et al 2004) 
and is also a major risk factor for lower extremity amputa-
tion (2003). However, PAD is not the most common cause 
of foot ulceration, and is a component factor in only about a 
quarter of all cases (Edmonds 1987; Thompson et al 1991). In 
a recent two-center study PAD partially contributed to 30% 
of all foot ulcers (Reiber et al 1999). Vascular assessment 
should include palpation of all lower extremity pulses, in-
cluding femoral, popliteal, posterior tibial, and dorsalis pedis 
pulses. The palpation of pulses is a learned skill with a high 
degree of inter-observer variability and high false positive 
and false negative rates (2003). The dorsalis pedis pulse has 
been reported to be absent in 8.1% of healthy individuals and 
the posterior tibial pulse is absent in 2.0% (2003). Although 
the absence of both pedal pulses when assessed by a person 
experienced in this technique, strongly suggests the presence 
of vascular disease, the presence of palpable pulses cannot 
exclude peripheral vascular disease. Ankle brachial pressure 
index (ABPI) (Figure 1), in contrast to the variability of pulse 
assessment and the often nonspeciﬁc nature of information 
obtained via history, is an easily reproducible and reasonably 
Figure 1  Obtaining ankle brachial pressure index.Vascular Health and Risk Management 2007:3(1) 68
Wu et al
accurate method of diagnosing vascular insufﬁciency in 
the lower limbs (2003). However, a normal ABPI may be 
deceiving, as medial arterial calciﬁcation of the foot vessels 
results in hardening of the arteries thereby falsely elevating 
the ankle brachial pressure index (Brooks et al 2001; Bonham 
2006). Parameswaran et al (2005) assessed doppler waveform 
of lower extremity arteries, ABI and pulse oximetry in 57 
consecutive patients with type 2 diabetes and no symptoms 
of PAD and found that 31% of the patients had PAD in the 
lower extremity (Parameswaran et al 2005). The authors 
noted that ABPI only had a sensitivity of 63% (95% CI, 
46%–77%) and a speciﬁcity of 97% (95% CI, 91%–99%) 
(Parameswaran et al 2005).
In addition, clinical evidence of dependent rubor, pallor 
on elevation, absence of hair growth, dystrophic toenails, and 
cool, dry, ﬁssured skin should also be noted as they may be 
concomitant signs of vascular insufﬁciency (2003).
Due to the high estimated prevalence of PAD in patients 
with diabetes, the ADA consensus statement issued the fol-
lowing recommendations (2003).
A screening ABPI be performed in all diabetic patients 
>50 years of age; if the results are normal, the test should be 
repeated every 5 years.
A screening ABPI should be considered in patients with 
diabetes <50 years of age who have other peripheral arterial 
disease risk factors. These risk factors include smoking, 
hypertension, hyperlipidemia, or duration of diabetes >10 
years.
A diagnostic ABPI should be performed in any patient 
with symptoms of PAD.
Protective sensation
Protective sensation, a level of sensory loss that allows 
patients to hurt themselves without recognizing injury, is a 
major component of nearly all diabetic ulcerations (Reiber 
et al 1999). The consequent vulnerability to physical and 
thermal trauma increases the risk of foot ulceration seven-
fold (Singh et al 2005). All patients with diabetes should be 
screened for loss of protective sensation to identify those at 
risk for foot ulceration (Olaleye et al 2001; Singh et al 2005). 
The absence of protective sensation may be determined 
using simple, non-invasive instruments such as a 128 Hz 
tuning fork, a Semmes-Weinstein 5.07/10 gram monoﬁla-
ment nylon wire, a calibrated vibration perception threshold 
(VPT) meter, or by a comprehensive physical examination 
(Abbott et al 2002).
The conventional 128 Hz tuning fork test is an easy and 
inexpensive tool to assess vibratory sensation. The tuning 
fork is held over bony prominences such as the ﬁrst metatar-
sal head and the lateral malleolus (Figure 2), and the test is 
considered positive when the patient is unable to perceive any 
vibration that the examiner can perceive (Singh et al 2005). 
The 5.07/10 g Semmes Weinstein monoﬁlament consists 
of a plastic handle supporting a nylon ﬁlament (Figure 3) 
and is one of the most frequently utilized screening tools 
to identify loss of protective sensation in the United States 
(Armstrong 2000; Singh et al 2005). Testing via the Semmes 
Weinstein monoﬁlament is administrated with the patient 
sitting supine in the examination chair with both feet level. 
The monoﬁlament is applied perpendicular to the skin until 
it bends or buckles from the pressure, left in place for ap-
proximately one second and then released (Singh et al 2005). 
The patient with his or her eyes closed responds “yes” each 
time he or she perceives the application of the monoﬁlament.   
Figure 2 Use of 128 Hz tuning fork.
Figure 3 Semmes Weinstein monoﬁlament. The monoﬁlament is applied  
perpendicular to the skin until it bends or buckles from the pressure, left in place 
for approximately one second and then released.Vascular Health and Risk Management 2007:3(1) 69
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The patient’s inability to perceive 10 g of force applied by 
the 5.07 monoﬁlament is clinically signiﬁcant for large-ﬁber 
neuropathy. Although vibratory testing has demonstrated 
greater sensitivity (Sorman and Edwall 2002), the Semmes 
Weinstein monoﬁlament test is sensitive enough to identify 
patients with the highest risk of foot complications (Gin   
et al 2002; Sorman and Edwall 2002).
The VPT meter, also known as Biothesiometer or Neu-
rothesiometer, is a hand-held device with a rubber tactor 
that vibrates at 100 Hz. The hand-held device is connected 
to a base unit displaying a linear scale of applied voltage, 
ranging from 0 to 100 v (Armstrong 1999; Pham et al 2000). 
The device is generally held with the rubber tactor balanced 
vertically on the pulp of the big toe. The voltage is increased 
until the patient perceives a vibration. A mean of three read-
ings measured in Volts is generally used to determine the 
vibration perception threshold for each foot. In a prospective 
four year study, a vibration perception threshold greater than 
25 v had a sensitivity of 83%, a speciﬁcity of 63%, a positive 
likelihood ratio of 2.2, and a negative likelihood ratio of 0.27 
for predicting foot ulceration (Young et al 1994; Mason et al 
1999). A comparison of the screening methods is illustrated 
in Table 1. 
Foot deformities and biomechanics
Foot deformities and limited joint mobility impose excessive 
pressure on the plantar aspect of the foot. This limitation in 
joint mobility is secondary to non-enzymatic glycosylation of 
periarticular soft tissues and reduces the foot’s ability to ac-
commodate for ambulatory ground reactive force to increase 
plantar pressure (Fernando et al 1991; Birke et al 1995; Lave-
ry et al 1995; Frykberg et al 1998; Armstrong et al 1999; Van 
Damme and Limet 2005). This excessive pressure combined 
with the repetitive or constant stress from daily ambulation 
along with neuropathy will ultimately lead to failure of the 
protective integument and ulceration (Figure 4). Although 
the precise pathophysiological mechanisms underlying the 
development of diabetic foot ulcerations are complex (Van 
Damme and Limet 2005), it is generally associated with the 
presence of peripheral neuropathy and repetitive trauma 
due to normal walking activities which exposes the foot to 
moderate or high pressure and shear forces (Brand 1991; 
Cavanagh et al 2005; Wu et al 2005). Brand (1983) theorized 
that local inﬂammatory response, focal tissue ischemia, tissue 
destruction, and ulceration may occur when these types of 
forces are applied to a speciﬁc area over an extended period 
of time. Ulceration sites correlate with the highest plantar 
pressure points (Duckworth et al 1982; Boulton 1987; Birke 
et al 1991; Cavanagh et al 1996; Armstrong et al 1998). Foot 
deformities, limited joint mobility, partial foot amputations 
and other structural deformities often predispose diabetic 
persons with peripheral neuropathy to abnormal weight bear-
ing areas of concentrated pressure that signiﬁcantly increase 
their risk of ulceration (Lavery et al 1995; Boulton 1996; 
Lavery et al 1996). In one study of patients with peripheral 
neuropathy, 28% with high plantar pressure developed a foot 
ulcer during a 2.5 year follow-up compared with none with 
normal pressure (Veves et al 1992).
Lavery et al reported that patients with neuropathy but no 
deformity or history of ulcer or amputation are at 1.7 times 
greater risk for ulceration compared with patients without neu-
ropathy (Lavery et al 1998). Neuropathy with concomitant 
Table 1 Comparison of screening methods to help identify persons with diabetes at increased risk for foot ulceration
  Tuning fork  Monoﬁlament  Biothesiometer
No. and type of   1 case control study   3 prospective cohort studies  2 prospective cohort studies 
studies  (Coppini et al 1998); 1   (Rith-Najarian et al 1992;   (Young et al 1994; Pham et al    
  prospective cohort study   Boyko et al 1999; Pham   1998) 
  (Boyko et al 1999)  et al 2000)   
Criteria for  Patient loses vibration  ≥1 insensate site  Vibration perception 
positive screening  while examiner still    threshold >25 v
test result  perceives it      
Sensitivity, %   55–61  66–91  83–86
Speciﬁcity, %  59–72  34–86   57–63
Predictive Value %
Positive   16*  18–39  20–32
Negative  93*87  94–95  95–97
Likelihood ratio
Positive    1.5–2.0  1.4–4.7  2.0–2.2
Negative  0.63-0.66  0.3–0.5  0.3
Note: *Data not available in case-control study to calculate a positive and a negative predictive value. Vascular Health and Risk Management 2007:3(1) 70
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deformity or limited joint mobility yields a 12.1 times greater 
risk, and patients with a history of previous ulceration or 
amputation have a 36.4 times greater risk for presenting with 
another ulcer. Additional studies by Peters and Lavery, and 
Mayﬁeld and co-workers (2001) by and large support these 
ﬁndings (Mayﬁeld et al 1996; Peters and Lavery 2001).
Other contributing factors
Clinicians should also examine the patient for other con-
tributing risk factors. Cutaneous manifestations associated 
with diabetes such as dry or ﬁssured skin, calluses, tinea, or 
onychomycosis should all be noted.
Patient education
Educating patients at risk for diabetic foot ulceration have 
been shown to be beneﬁcial (Malone et al 1989; Litzelman 
et al 1993; Singh et al 2005). Malone et al (1989) assessed 
the effectiveness of diabetic foot education by randomizing 
103 patients (203 limbs) to receiving an hour foot care edu-
cation and 100 patients (193 limbs) to receiving an hour of 
general diabetes mellitus education for 24 months total. The 
authors noted a lower incidence of foot ulcers in the group 
that received an hour of foot care education (4.5% vs 14.7%; 
RR, 0.31 [95% CI, 0.14 to 0.66]; ARR, –0.10 [95% CI, –0.16 
to –0.04]; p = .002) (Malone et al 1989). Litzelman and co-
workers (1993) conducted sessions on foot care, telephone 
reminders, and postcard reminders in 191 patients and gave 
standard care to 205 patients for a period of 12 months and 
noted fewer serious foot lesions in the group that received 
sessions on foot care and telephone/postcard reminders (OR, 
0.41 [95% CI, 0.16–1.00]; p =.05) (Litzelman et al 1993).
Patients along with their family members or care takers 
should understand the implications of the loss of protective 
sensation, and the importance of daily foot examinations and 
the proper foot care (Mayﬁeld et al 2003).
Treatment
There have been advances in managing diabetic foot ulcer-
ation with the development of new dressings, growth factors, 
bioengineered skin and tissue substitutes, hyperbaric oxygen, 
negative pressure wound therapy, and other novel approaches 
to stimulate wound healing (Steed 1995; Steed et al 1996; 
Figure 4 Neuropathic foot ulceration secondary to excessive pressure (from foot deformity) in combination with the repetitive stress from daily ambulation.Vascular Health and Risk Management 2007:3(1) 71
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Gough et al 1997; Donaghue et al 1998; 2000; Hopf et al 
2001). Allogeneic bi-layered cultured skin equivalent (Apli-
graf, Organogenesis Inc., Canton, MA) is a living, biological 
dressing developed from neonatal foreskin and consists of 
living cells and structural proteins. It is FDA approved for the 
treatment of diabetic foot ulcers (2000) and was shown to heal 
more noninfected, nonischemic chronic plantar diabetic foot 
ulcers faster and in more patients than conventional therapy 
in a large-scale multi-center randomized prospective clinical 
trial (Veves et al 2001). Becaplermin (Regranex, Johnson 
& Johnson, New Brunswick, NJ) is a hydrogel that contains 
0.01% platelet derived growth factor-BB (rhPDGF-BB) and 
is currently the only commercially available topical growth 
factor for use in cutaneous wound healing. Although the   
efficacy becaplermin has been demonstrated in several 
studies (Rees et al 1999; Embil et al 2000) this has not been 
translated equivocally onto daily practice. It has been sug-
gested that bercaplermin’s lack of clinical success may be 
secondary to the imbalance between levels of matrix metal-
loproteases and their inhibitors in the ﬂuids of ulcers causes 
elevated levels of proteases (Yager et al 1996). The proteases 
in turn destroy essential growth factors, extracellular matrix 
proteins, and receptors, including the ones speciﬁc for PDGF-
BB to ultimately prevent wounds from healing (Ladwig et 
al 2002). Many suggest combining bercaplermin gel with 
collagen and oxidized regenerated cellulose to help bind the 
matrix metalloproteases and potentiate becaplermin’s effects 
on wound healing.
Collagen and oxidized regenerated cellulose (Promogran, 
Johnson & Johnson, New Brunswick, NJ) is a sterile, freeze 
dried matrix sheet. ORC absorbs wound exudate and forms 
a soft, biodegradable gel that binds and inactivates matrix 
metalloproteases (MMP) which have been shown to have a 
detrimental effect on wound healing when present in exces-
sive quantities (Wysocki et al 1993; Ladwig et al 2002). 
In addition, ORC binds growth factors within the wound, 
protects them from degradation and releases them back into 
the wound in an active form as the matrix is slowly broken 
down. The effectiveness of ORC has been demonstrated in 
several studies (Vin et al 2002; Omugha and Jones 2003).
Negative pressure wound therapy (Vacuum Assisted 
Closure, Kinetic Concepts Inc., San Antonio, TX) is a non-
invasive wound closure system that uses controlled, localized 
sub-atmospheric pressure to help promote healing in chronic 
and acute wounds. This sub-atmospheric or negative pres-
sure can be conveyed either continuously or intermittently 
though a sterile, latex free polyurethane or polyvinyl alcohol 
foam dressing. Negative Pressure Wound Therapy has been 
advocated my numerous authors as a safe and effective   
adjunctive modality in the treatment of diabetic foot wounds 
(Armstrong et al 2002; Eginton et al 2003; Armstrong and 
Lavery 2005; Mendonca et al 2005).
Despite these advances, it is imperative to remember the 
fundamental basics in the healing of diabetic foot ulcers: 
adequate perfusion, debridement, infection control, and 
pressure mitigation.
Vascularity
Adequate vascular perfusion is of utmost importance in 
wound healing (Dang and Boulton 2003). If pulses are not 
palpable, doppler ultrasound, ankle-brachial blood pres-
sure indices as well as other non-invasive vascular studies 
such as segmental pressures, pulse volume recordings, and 
transcutaneous oxygen tension are warranted. A prompt 
vascular surgery consult and possible intervention such as 
angioplasty, stenting, or femorodistal bypass to improve 
perfusion and thereby effect healing is also indicated 
(Cavanagh et al 2005).
Infection control
Since infection is not well deﬁned, the genesis, diagnosis 
and resolution of infection remains a clinical endeavor 
(Cavanagh et al 2005). Cultures, laboratory results, and 
subjective symptoms are helpful adjuncts. Wound cultures 
reveal the causative pathogens, however, tissue specimens 
are strongly preferred over wound swabs for wound cultures 
(Cavanagh et al 2005). While the diagnostic criteria for 
infection are imprecise, there is little doubt that infection is 
a major cause of lower extremity morbidity that frequently 
eventuates into wet gangrene and subsequent amputation. 
Antimicrobial therapy should be guided by culture results, 
focused at curing the infection rather than healing the wound 
(Cavanagh et al 2005).
Debridement
Debridement, the removal of hyperkeratotic and devital-
ized tissue, foreign materials, and particulate matter from 
a wound, is often the key ﬁrst step of effective wound care 
(Lewis et al 2001; Armstrong et al. 2004; Steed 2004). 
Debridement helps reduce the rate of infection and pro-
vides an ideal healing environment by converting chronic 
wounds into acute (Falanga 2004). Wound debridement 
helps reduce chronic inﬂammatory byproducts (Nwomeh 
et al 1999; Jude et al 2001; Armstrong and Jude 2002) and 
may be accomplished surgically, chemically, mechanically, 
biologically, or by autolysis (Lewis et al 2001). Sharp or Vascular Health and Risk Management 2007:3(1) 72
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surgical debridement, the most direct and efﬁcient method to 
clean the woundbed (Blanke and Hallern 2003), is generally 
considered the gold standard.
In addition to the wound base, it is also important 
to debride wound margins to mitigate the “edge effect” 
(Armstrong and Athanasiou 1998; Armstrong et al. 2004) 
(Figure 5). The edge effect is secondary to the skin interrup-
tion which increases both vertical and shear stresses on the 
edges of that interruption (Armstrong and Athanasiou 1998). 
The vertical force progressively deepens the wound, while the 
shear force from the underlying epithelium widens the wound 
via undermining (Armstrong and Athanasiou 1998).
Pressure mitigation
With sufﬁcient vascular supply, appropriate debridement, moist 
wound environment, and infection control, the primary mode of 
healing a diabetic neuropathic foot ulcer is pressure dispersion 
(Armstrong et al 2004; Wu et al 2005). Of the plethora of ofﬂoad-
ing modalities including bed rest, wheel chairs, crutches, total 
contact casts, felted foam, half shoes, therapeutic shoes, custom 
splints, and removable cast walkers, total contact casting (TCC) 
(Figure 6) is considered by many to be the “gold standard” in 
achieving pressure redistribution (Coleman et al 1984; Walker 
et al 1985; Boulton et al 1986; Sinacore et al 1987; Walker et al 
1987; Kominsky 1991; Lavery et al 1997). TCC has been shown 
to reduce pressure at the site of ulceration by 84%–92% (Lavery et 
al 1996) and is quite effective with healing rates ranging from 72% 
Figure 5 Debridement of wound margins to mitigate the “edge effect”.
Figure 6 Total contact cast.Vascular Health and Risk Management 2007:3(1) 73
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to 100% over a course of 5–7 weeks (Helm et al 1984; Walker et 
al 1985; Sinacore et al 1987; Walker et al 1987; Myerson et al. 
1992). However, the application of TCC is time consuming and 
often associated with a learning curve. Most centers do not have 
a physician or cast technician available with adequate training or 
experience to safely apply a TCC; improper cast application can 
cause skin irritation and in some cases even frank ulceration. In 
addition TCCs do not allow daily assessment of the foot or wound 
and are therefore often contraindicated in cases of soft tissue or 
bone infections. Recent studies have shown that an instant total 
contact cast (iTCC), made by simply wrapping a removable cast 
walker with a single layer of cohesive bandage, elastoplast, or 
casting tape (Figure 7a, b, c), may be just as effective as a TCC in 
pressure mitigation and the healing of diabetic foot ulcers (Wu et 
al 2005). A randomized controlled study compared the standard 
TCC with an iTCC (Katz et al 2005) and found no differences 
in healing rates and mean healing time between patients who 
received the TCC versus the iTCC . The proportions of patients 
that healed within 12 weeks in the iTCC and TCC groups were 
80% and 74%, respectively (Katz et al 2005). There were no 
differences in complications between the two groups, however, 
the cost in materials and personnel was much lower for the iTCC 
compared with the TCC. The study concluded that the iTCC is 
not only equally efﬁcacious in healing diabetic foot ulcers, when 
compared with the TCC but is quicker, easier, and more cost ef-
fective than the TCC (Katz et al 2005).
Conclusion
There is a high occurrence of foot ulcers within the population 
of people with diabetes. Foot ulcerations may lead to infections, 
lower extremity amputations and are major causes of disability 
to patients, often resulting in signiﬁcant morbidity, extensive 
periods of hospitalization, and mortality. In order to diminish the 
detrimental consequences associated with diabetic foot ulcers, a 
high standard of care must be provided. Many of the etiological 
Figure 7a Removable cast walker.
Figure 7b Instant total contact cast: made by wrapping the removable cast walker 
with a layer of cohesive bandage.Vascular Health and Risk Management 2007:3(1) 74
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factors contributing to the formation of diabetic foot ulceration 
may be identiﬁed using simple, inexpensive equipment in a 
clinical setting, and early recognition of these factors along with 
prompt management of the ulcers are essential for successful 
outcome (Van Damme and Limet 2005). Aggressive treatment 
of infections, correction of vascular occlusive disease, adequate 
wound care, and appropriate pressure mitigation are essential 
steps in the treatment protocol (Van Damme and Limet 2005). 
With the implementation of good prevention and treatment pro-
grams, a signiﬁcant reduction of lower extremity complications 
well within reach. 
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